The Effect of Acarbose on Inflammatory Cytokines and Adipokines in Adults: a Systematic Review and Meta-analysis of Randomized Clinical Trials

Overview

Journal Inflammopharmacology

Specialty Pharmacology

Date 2024 Jan 3

PMID 38170330

Authors

Ali Mohammadian

Sahand Tehrani Fateh

Mahlagha Nikbaf-Shandiz

Fatemeh Gholami

Niloufar Rasaei

Hossein Bahari

Samira Rastgoo

Reza Bagheri

Farideh Shiraseb

Omid Asbaghi

Affiliations

Soon will be listed here.

Abstract

Background: Although a large number of trials have observed an anti-inflammatory property of acarbose, the currently available research remains controversial regarding its beneficial health effects. Hence, the purpose of this study was to examine the effect of acarbose on inflammatory cytokines and adipokines in adults.

Methods: PubMed, Web of Science, and Scopus were systematically searched until April 2023 using relevant keywords. The mean difference (MD) of any effect was calculated using a random-effects model. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated via the random-effects model.

Results: The current meta-analysis of data comprised a total of 19 RCTs. Meta-analysis showed that acarbose significantly decreased tumor necrosis factor-alpha (TNF-α) (weighted mean difference [WMD]) = - 4.16 pg/ml, 95% confidence interval (CI) - 6.58, - 1.74; P = 0.001) while increasing adiponectin (WMD = 0.79 ng/ml, 95% CI 0.02, 1.55; P = 0.044). However, the effects of acarbose on TNF-α concentrations were observed in studies with intervention doses ≥ 300 mg/d (WMD = - 4.09; 95% CI - 7.00, - 1.18; P = 0.006), and the adiponectin concentrations were significantly higher (WMD = 1.03 ng/ml, 95%CI 0.19, 1.87; P = 0.016) in studies in which the duration of intervention was less than 24 weeks. No significant effect was seen for C-reactive protein (CRP; P = 0.134), interleukin-6 (IL-6; P = 0.204), and leptin (P = 0.576).

Conclusion: Acarbose had beneficial effects on reducing inflammation and increasing adiponectin. In this way, it may prevent the development of chronic diseases related to inflammation. However, more studies are needed.

References

Anubhuti , Arora S . Leptin and its metabolic interactions: an update. Diabetes Obes Metab. 2008; 10(11):973-93. DOI: 10.1111/j.1463-1326.2008.00852.x. View

Bahari H, Rafiei H, Goudarzi K, Omidian K, Asbaghi O, Hosseini Kolbadi K . The effects of pomegranate consumption on inflammatory and oxidative stress biomarkers in adults: a systematic review and meta-analysis. Inflammopharmacology. 2023; 31(5):2283-2301. DOI: 10.1007/s10787-023-01294-x. View

Bahari H, Taheri S, Rashidmayvan M, Jamshidi S, Shahraki Jazinaki M, Pahlavani N . The effect of Royal jelly on liver enzymes and glycemic indices: A systematic review and meta-analysis of randomized clinical trials. Complement Ther Med. 2023; 77:102974. DOI: 10.1016/j.ctim.2023.102974. View

Chiasson J . Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006; 12 Suppl 1:25-30. DOI: 10.4158/EP.12.S1.25. View

Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A . Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab. 2002; 28(3):195-200. View

Derosa G, DAngelo A, Salvadeo S, Ferrari I, Fogari E, Gravina A . Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. Biomed Pharmacother. 2009; 63(10):723-33. DOI: 10.1016/j.biopha.2009.04.044. View

Derosa G, Maffioli P, Ferrari I, Fogari E, DAngelo A, Palumbo I . Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol. 2010; 651(1-3):240-50. DOI: 10.1016/j.ejphar.2010.11.015. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

DiNicolantonio J, Bhutani J, OKeefe J . Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart. 2015; 2(1):e000327. PMC: 4620230. DOI: 10.1136/openhrt-2015-000327. View

10.

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

11.

Fukaya N, Mochizuki K, Shimada M, Goda T . The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. Nutrition. 2009; 25(6):657-67. DOI: 10.1016/j.nut.2008.11.015. View

12.

Fulop N, Mason M, Dutta K, Wang P, Davidoff A, Marchase R . Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart. Am J Physiol Cell Physiol. 2006; 292(4):C1370-8. DOI: 10.1152/ajpcell.00422.2006. View

13.

Fulop N, Marchase R, Chatham J . Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. Cardiovasc Res. 2006; 73(2):288-97. PMC: 2848961. DOI: 10.1016/j.cardiores.2006.07.018. View

14.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

15.

Haffner S, Hanefeld M, Fischer S, Fucker K, LEONHARDT W . Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care. 1997; 20(9):1430-4. DOI: 10.2337/diacare.20.9.1430. View

16.

Hanefeld M . Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus). Endocr Pract. 2006; 12 Suppl 1:56-9. DOI: 10.4158/EP.12.S1.56. View

17.

Hanefeld M, Schaper F, Koehler C, Bergmann S, Ugocsai P, Stelzer J . Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study. Horm Metab Res. 2009; 41(2):132-6. DOI: 10.1055/s-0028-1119407. View

18.

Harrison D, Strong R, Allison D, Ames B, Astle C, Atamna H . Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2013; 13(2):273-82. PMC: 3954939. DOI: 10.1111/acel.12170. View

19.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

20.

Hirano M, Nakamura T, Obata J, Fujioka D, Saito Y, Kawabata K . Early improvement in carotid plaque echogenicity by acarbose in patients with acute coronary syndromes. Circ J. 2012; 76(6):1452-60. DOI: 10.1253/circj.cj-11-1524. View